Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

被引：3
作者：
Zhao, Menglu [1 ]
Yan, Chun-Yan [1 ]
Wei, Ya-Nan [1 ]
Zhao, Xi-He [1 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Clin Oncol, Shenyang 110022, Peoples R China
来源：
ANTIVIRAL RESEARCH | 2023年 / 219卷
基金：
中国国家自然科学基金;
关键词：
PD-L1; Drug resistance; Bispecific antibody; Antibody drug conjugate (ADC); TUMOR MUTATIONAL BURDEN; T-CELLS; ANTITUMOR IMMUNITY; CANCER; IMMUNOTHERAPY; BLOCKADE; EFFICACY; RECEPTOR; PD-L1; EXPRESSION;
D O I：
10.1016/j.antiviral.2023.105720
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/ PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapyresistant cancer.
引用
收藏
页数：11
相关论文
共 50 条
  • [41] Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
    Olbryt, Magdalena
    Rajczykowski, Marcin
    Widlak, Wieslawa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 20
  • [42] Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
    Sivapiragasam, Abirami
    Kumar, Prashanth Ashok
    Sokol, Ethan S.
    Albacker, Lee A.
    Killian, Jonathan K.
    Ramkissoon, Shakti H.
    Huang, Richard S. P.
    Severson, Eric A.
    Brown, Charlotte A.
    Danziger, Natalie
    McGregor, Kimberly
    Ross, Jeffrey S.
    CANCER MEDICINE, 2021, 10 (01): : 53 - 61
  • [43] Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
    Marchini, Antonio
    Scott, Eleanor M.
    Rommelaere, Jean
    VIRUSES-BASEL, 2016, 8 (01):
  • [44] The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges
    Bouferraa, Youssef
    Chedid, Andrea
    Amhaz, Ghid
    El Lakkiss, Ahmed
    Mukherji, Deborah
    Temraz, Sally
    Shamseddine, Ali
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (15)
  • [45] Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
    Lei, Yanna
    Li, Xiaoying
    Huang, Qian
    Zheng, Xiufeng
    Liu, Ming
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
    Liu, Shui
    Geng, Shuai
    Shi, Ning
    Zhang, Lili
    Xue, Wenxin
    Li, Yiwen
    Jiang, Kai
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
    Frankel, Arthur E.
    Deshmukh, Sachin
    Reddy, Amit
    Lightcap, John
    Hayes, Maureen
    McClellan, Steven
    Singh, Seema
    Rabideau, Brooks
    Glover, T. Grant
    Roberts, Bruce
    Koh, Andrew Y.
    INTEGRATIVE CANCER THERAPIES, 2019, 18
  • [48] Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
    Jia, Yunlong
    Liu, Lihua
    Shan, Baoen
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
  • [49] Immune Checkpoint Inhibitors in Human Glioma Microenvironment
    Ghouzlani, Amina
    Kandoussi, Sarah
    Tall, Mariam
    Reddy, Konala Priyanka
    Rafii, Soumaya
    Badou, Abdallah
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [50] Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    CANCERS, 2021, 13 (05) : 1 - 10
12345